Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)'s revenue for the
six
months ended in Dec. 2025 was $1,681 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $3,067 Mil.
WuXi Biologics (Cayman)'s Revenue per Share for the
six
months ended in Dec. 2025 was $0.40.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.73.
Good Sign:
WuXi Biologics (Cayman) Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of WuXi Biologics (Cayman) was 22.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 26.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 41.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, WuXi Biologics (Cayman)'s highest 3-Year average Revenue per Share Growth Rate was 65.30% per year. The lowest was 13.90% per year. And the median was 50.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Revenue distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $3,067 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a Revenue of $3,067 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Revenue too high?
WuXi Biologics (Cayman)'s current Revenue is $3,067 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Revenue compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Revenue of $3,067 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Revenue is $3,067 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.16, compared to a current price of $4.60 — trading 10.9% below its estimated fair value. The current Revenue is $3,067 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Revenue is $3,067 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.60 is trading 10.9% below its estimated GF Value™ of $5.16.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for WXIBF:
Revenue: $3,067 Mil
GF Value™: $5.16 vs. price of $4.60 (10.9% below fair value)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
